PIK3CA and vascular malformation: Sirolimus is the standard treatment for painful inflammatory manifestations of low‐flow vascular malformations such capillary, venous, and lymphatic malformations that can occur singly or in combination but PIK3CA inhibitors, originally developed in oncology, have shown promising results in patients with PIK3CA‐related overgrowth spectrum.